Hydrocortisone Activase

Hydrocortisone Activase is an oral prescription medication containing the corticosteroid hydrocortisone. It is marketed in the European Union and is formulated for systemic use. As a glucocorticoid, it provides anti‑inflammatory and immunosuppressive effects. The product is supplied without a specified strength or dosage form in this description, and it requires a healthcare professional’s prescription. It is intended for patients diagnosed with adrenal insufficiency or inflammatory and autoimmune conditions, under supervision.

Hydrocortisone Activase is prescribed for conditions that require systemic glucocorticoid therapy.

- Replacement therapy for primary or secondary adrenal insufficiency. - Management of acute exacerbations of chronic inflammatory diseases such as rheumatoid arthritis. - Treatment of severe allergic reactions when oral corticosteroids are indicated. - Adjunctive therapy for certain autoimmune disorders, for example systemic lupus erythematosus. - Short‑term control of inflammation in dermatologic or gastrointestinal conditions when oral administration is preferred.

Oral hydrocortisone may cause a range of adverse reactions, varying in frequency and severity.

Common: - Mild gastrointestinal upset such as nausea or dyspepsia. - Transient increase in blood glucose levels, especially in diabetic patients. - Fluid retention leading to mild peripheral edema. - Mood changes including irritability or insomnia.

Serious: - Severe hyperglycemia or new‑onset diabetes mellitus. - Suppression of the hypothalamic‑pituitary‑adrenal axis causing adrenal crisis on abrupt discontinuation. - Opportunistic infections due to immunosuppression.

Before initiating Hydrocortisone Activase, clinicians should evaluate several safety considerations.

- Assess for active infections, as glucocorticoids can worsen bacterial, viral, or fungal diseases. - Screen for uncontrolled diabetes or hypertension, conditions that may be exacerbated. - Evaluate history of peptic ulcer disease; concurrent NSAIDs increase gastrointestinal risk. - Consider bone health, especially in long‑term therapy, due to risk of osteoporosis. - Use the lowest effective dose and taper gradually to avoid adrenal insufficiency. - Counsel pregnant or breastfeeding patients, as safety data are limited.

Hydrocortisone Activase can interact with other medicines, altering efficacy or safety.

Avoid: - Concurrent use with potent CYP3A4 inducers (e.g., rifampin, phenytoin) that may reduce hydrocortisone exposure. - Combining with other systemic corticosteroids, which can increase risk of systemic side effects. - Use with strong immunosuppressants (e.g., cyclosporine) without monitoring, due to additive infection risk.

Use with caution: - Concomitant antidiabetic agents; hydrocortisone may raise glucose and require dose adjustment. - Non‑steroidal anti‑inflammatory drugs (NSAIDs) may increase gastrointestinal bleeding risk. - Anticoagulants such as warfarin; glucocorticoids can affect clotting factor synthesis. - Vaccines, especially live attenuated, may have reduced efficacy or cause infection.